6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00479401 (ClinicalTrials.gov)	May 2007	25/5/2007	Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients	A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).	Early Parkinson Disease (Early PD)	Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	All	539	Phase 3	United States;Argentina;Austria;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;Brazil
2	NCT00466167 (ClinicalTrials.gov)	April 2007	25/4/2007	Pivotal Study in Advanced Parkinsons Disease Patients	A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).	Parkinson Disease	Drug: Pramipexol Extended Release;Drug: Pramipexol Immediate Release;Drug: Placebo	Boehringer Ingelheim	NULL	Completed	32 Years	N/A	All	517	Phase 3	Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom